Home › Research › Clinical trials
The Women's Health Initiative Memory Study: findings and implications for treatment
Craig MC, Maki PM, Murphy DG.. The Lancet. Neurology, 2005-03-01
Topic: Risk, prevention and care in population studies
Plain-language summary
Background The population of the developed world is ageing; consequently there is an increasing prevalence of age-related neuropsychiatric disorders, such as dementia of any cause and Alzheimer's disease (AD), for which few treatments are available. Observational studies suggested that hormone therapy (HT) might protect postmenopausal women against cognitive decline and AD. However, the results of randomised controlled trials in women age 65 years and older were negative. There has been extensive media coverage of these trials and many doctors are asked whether HT improves or worsens brain function in younger women who are prescribed HT for the treatment of menopausal symptoms. Recent developments The Women's Health Initiative Memory Study (WHIMS) was a multicentre, randomised, double-blind, placebo-controlled clinical trial in which a subgroup of women who participated in the Women's Health Initiative study were assessed for the effects of HT on dementia and mild cognitive impairment. There were two study arms, one involving 4532 postmenopausal women who received continuous combined oestrogen (conjugated equine oestrogens [CEE] plus medroxyprogesterone acetate) or placebo, and the other involving 2947 hysterectomised women randomised to continuous unopposed CEE or placebo. All participants were age 65 years or older. CEE with or without medroxyprogesterone acetate, given to women age 65 years and older, does not protect against dementia or cognitive decline, but substantially increases the risk of dementia of any cause and cognitive decline. WHERE NEXT?: WHIMS answered critically important questions about whether HT can protect against dementia in elderly women who start HT some years after menopause. However, several clinically important questions are unanswered, including questions about the generalisability of WHIMS to groups of women for whom HT is an indication-perimenopausal women and those soon after menopause who have menopausal symptoms-and other methods of treatment delivery and treatment regimens.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Craig, M. C., Maki, P. M., & Murphy, D. G. (2005). The Women's Health Initiative Memory Study: findings and implications for treatment. The Lancet. Neurology. https://doi.org/10.1016/s1474-4422(05)01016-1
Vancouver
Craig MC, Maki PM, Murphy DG. The Women's Health Initiative Memory Study: findings and implications for treatment. The Lancet. Neurology. 2005. doi:10.1016/s1474-4422(05)01016-1. PMID: 15721829.
BibTeX
@article{craig2005-15721829,
author = {Craig, M. C. and Maki, P. M. and Murphy, D. G.},
title = {{The Women's Health Initiative Memory Study: findings and implications for treatment}},
journal = {The Lancet. Neurology},
year = {2005},
doi = {10.1016/s1474-4422(05)01016-1},
pmid = {15721829},
url = {https://doi.org/10.1016/s1474-4422(05)01016-1}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Observational studies suggested that hormone therapy (HT) might protect postmenopausal women against cognitive decline and AD.
- However, the results of randomised controlled trials in women age 65 years and older were negative.
New to this subject? Start with our plain-English guide: Registered clinical trials →
Study details
- Evidence strengthHigh
How this study scored 48/100
Published in a leading specialty journal. Scored zero for study design, sample size, effect reported and studied in people because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 28 of the 58 points we could judge it on, which is 48 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (The Lancet. Neurology) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2005 — older than 20 years, still counted |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 1 / 2 | Randomized (as stated in the record) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 15721829) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 28 / 58 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 28 of the 58 points we could judge it on is 48 out of 100. |
| Total | 48 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Clinical trials from nearby years
Also tagged “health-initiative”
2 studies in the library carry the topic tag “health-initiative”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 2 tagged studies.